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ABSTRACT
Objectives A policy model is a model that can
evaluate the effectiveness and cost-effectiveness of
interventions and inform policy decisions. In this study,
we introduce a cardiovascular disease (CVD) policy
model which can be used to model remaining life
expectancy including a measure of socioeconomic
deprivation as an independent risk factor for CVD.
Design A state transition model was developed using
the Scottish Heart Health Extended Cohort (SHHEC)
linked to Scottish morbidity and death records.
Individuals start in a CVD-free state and can transit to
three CVD event states plus a non-CVD death state.
Individuals who have a non-fatal ﬁrst event are then
followed up until death. Taking a competing risk
approach, the cause-speciﬁc hazards of a ﬁrst event are
modelled using parametric survival analysis. Survival
following a ﬁrst non-fatal event is also modelled
parametrically. We assessed discrimination, validation
and calibration of our model.
Results Our model achieved a good level of
discrimination in each component (c-statistics for men
(women)—non-fatal coronary heart disease (CHD): 0.70
(0.74), non-fatal cerebrovascular disease (CBVD): 0.73
(0.76), fatal CVD: 0.77 (0.80), fatal non-CVD: 0.74
(0.72), survival after non-fatal CHD: 0.68 (0.67) and
survival after non-fatal CBVD: 0.65 (0.66)). In general,
our model predictions were comparable with observed
event rates for a Scottish randomised statin trial
population which has an overlapping follow-up period
with SHHEC. After applying a calibration factor, our
predictions of life expectancy closely match those
published in recent national life tables.
Conclusions Our model can be used to estimate the
impact of primary prevention interventions on life
expectancy and can assess the impact of interventions
on inequalities.
INTRODUCTION
The Global Burden of Disease Study1 estimated
that in 2010 cardiovascular disease (CVD), includ-
ing rheumatic heart diseases, hypertensive diseases,
ischaemic heart diseases, pulmonary heart disease,
other forms of heart disease, cerebrovascular dis-
eases (CBVDs), diseases of arteries and diseases of
veins, was the cause of death in approximately 30%
of all global deaths. In Scotland, although mortality
rates have declined steadily for decades (eg, coron-
ary heart disease (CHD) mortality rates for men
were 72% lower in 2009 than in 1950), in 2009,
Scottish CHD mortality rates for men and women
were 39% and 64% higher, respectively, than the
average for Western Europe.2 Furthermore, despite
improvements, inequalities persist in Scotland. For
example, in 2011, the European age-standardised
CHD mortality rates for the most deprived ﬁfth of
the Scottish Index of Multiple Deprivation (SIMD)
scores3 were 62% higher than the corresponding
rates for the least deprived ﬁfth of SIMD scores.4
There are many types of CVD interventions (eg,
lifestyle, pharmaceuticals, legislation, etc.) which
aim to reduce the disease burden, ranging from
those that target the individual to those with popu-
lation coverage. Reimbursement agencies, such as
the National Institute for Health and Care
Excellence5 in England and Wales and the Scottish
Medicines Consortium6 in Scotland, require evi-
dence that interventions are cost-effective prior to
adoption. A challenge in generating this evidence is
that randomised trials are short term in nature and
so often modelling is necessary to predict longer
term cost-effectiveness.
A deﬁnition of a policy model is a model that
can evaluate the effectiveness and cost-effectiveness
of interventions and inform policy decisions. There
are a wide variety of CVD policy models in exist-
ence.7 A recent example,8 set in England and
Wales, uses Framingham risk equations to build a
model which can estimate the impact of potential
interventions in terms of CVD events prevented,
life years and quality-adjusted life years gained and
costs to the National Health Service. A limitation
of this model, as the authors acknowledge, is that it
uses a limited time frame (10 years) rather than a
lifetime perspective.
In developing a model to be used by policy
makers, it is important that the approach is consist-
ent with prediction models that are used in clinical
practice. The Scottish Intercollegiate Guidelines
Network9 has recommended the use of the
ASSIGN score10 as the clinical prediction tool for
prioritising individuals for primary prevention in
Scotland. A key feature of this score is the inclusion
of an area-based measure of socioeconomic depriv-
ation, SIMD,3 as an independent risk factor. This
has the potential to reduce inequalities because,
holding the other risk factors constant, people res-
iding in areas with higher levels of socioeconomic
deprivation will be given higher ASSIGN scores.
Furthermore, if the ASSIGN score is used in mod-
elling exercises to estimate the impact of new
Open Access
Scan to access more
free content
Lewsey JD, et al. Heart 2015;101:201–208. doi:10.1136/heartjnl-2014-305637 201
Healthcare delivery, economics and global health
group.bmj.com on April 21, 2015 - Published by http://heart.bmj.com/Downloaded from 
interventions, it also provides an assessment of how the new
intervention will affect the level of inequality.
The aim of our study is to develop a CVD policy model for
use in Scotland using the same risk factors as ASSIGN but
taking a lifetime perspective. The key outputs from this model
will be life expectancy, quality-adjusted life expectancy and life-
time healthcare costs. These outputs can be used in decision
analysis to assess the cost-effectiveness of interventions and their
impact on health inequalities. We will report our model in a
comprehensive and transparent manner, following best practice
guidelines.11
METHODS
We describe the methods below with additional technical details
available in the online supplementary appendix.
Model structure
As for ASSIGN, the endpoints of our model are non-fatal CHD
hospitalisation, non-fatal CBVD hospitalisation and deaths from
CVD. However, with the focus on life expectancy we also
needed to consider deaths from non-CVD causes and the add-
itional life expectancy experienced after a non-fatal CHD or
CBVD event. Figure 1 illustrates the structure of the state transi-
tion model. People enter the model in the CVD event-free state
and then transit into one of four events ‘competing’ to be ﬁrst.
If a hospitalised patient died within 28 days of their admission
the ﬁrst event was reclassiﬁed as fatal. If the ﬁrst event experi-
enced is non-fatal, then there is a ﬁnal transition to death. Men
and women were modelled separately.
Data source
The Scottish Heart Health Extended Cohort (SHHEC) is made
up of individuals from the Scottish Heart Health Study12 which
recruited random samples of the Scottish population between
1984 and 1987, and individuals from the Scottish MONICA
Project13 which recruited in Edinburgh in 1986 and North
Glasgow in 1986, 1989, 1992 and 1995. The SHHEC partici-
pants, aged between 25 and 74 years, attended a survey clinic
where cardiovascular risk factors were measured.
The data were linked to hospital admissions using the Scottish
Morbidity Record Scheme and deaths using the General
Register Ofﬁce (GRO) for Scotland. Risk factors used for mod-
elling the ﬁrst event were age at survey (years), systolic blood
pressure (SBP; mm Hg), total cholesterol (TC; mmol/L), high-
density lipoprotein (HDL) cholesterol (mmol/L), cigarettes per
day (CPD), self-reported diabetes, self-reported family history of
heart disease and SIMD score (2004 version). Risk factors used
for modelling death after a non-fatal ﬁrst event were age at ﬁrst
event, self-reported family history of heart disease and SIMD.
Any missing data in the risk factors were taken into account
using the multiple imputation of chained equations technique.14
It should be noted that the modiﬁable risk factors of SBP, TC,
HDL cholesterol and CPD can only directly inﬂuence the risk
of having a ﬁrst event as these variables were only measured at
baseline. Therefore, the focus of our policy model is to evaluate
primary prevention interventions.
Modelling stage 1: estimating risk of having ﬁrst event
Survival analysis was used to model the cause-speciﬁc hazards of
the competing ﬁrst events (equation 1 in ﬁgure 1). By the end of
follow-up not all SHHEC participants had experienced a ﬁrst
event, so a parametric approach (Gompertz regression) was
required to extrapolate the modelling so total remaining life
expectancy could be estimated. Predicted cumulative incidence
of events was calculated from the cause-speciﬁc hazards and the
probability of surviving from any of the competing events at a
given time.
Modelling stage 2: estimating life expectancy following
non-fatal CHD and CBVD events
Gompertz regression was also used to model the hazard of
death following a ﬁrst event (equation 2 in ﬁgure 1). Due to
censoring it was necessary to extrapolate the survival analysis to
a time point when for a given covariate proﬁle the probability
of surviving beyond that time point was zero. The area under
the survival curve was obtained by applying the trapezoidal
rule15 with half cycle correction and this provided an estimate
of remaining life expectancy.
Modelling stage 3: estimating overall life expectancy
The state transition model uses a cycle period of 1 year. At the end
of a model cycle an individual can either remain in the CVD-free
state or move to one of the four competing events. To calculate
remaining life expectancy, the model sums the time before an
event and survival time after non-fatal event (area under the sur-
vival curve). The model cycles annually for 100 years and within
each cycle the model estimates the consequences if each of the
competing ﬁrst events occurred. For example, if a person has a
non-fatal CHD event after 3 years the additional life expectancy is
those 3 years added to the life expectancy following the non-fatal
event predicted from the survival analysis (modelling stage 2).
Whereas, if a person dies of CVD causes after 3 years the add-
itional life expectancy is just those 3 years. All these ﬁrst event pos-
sibilities are weighted by the probability of that event occurring at
that particular time which comes from the predicted cumulative
incidence estimates (modelling stage 1).
For measuring inequalities in life expectancy, we calculated
the Slope Index of Inequality (SII)16 which takes into account
the whole distribution of life expectancy across the range of
SIMD.
Discrimination, validation and calibration of the model
The discrimination of the statistical models was assessed using
Harrell’s concordance statistic (c-statistic).17 It is important to
note this will only assess discrimination where we have observed
events to compare with the model predictions. As a validation
exercise, we used the West of Scotland Coronary Prevention
Study (WOSCOPS)18 to test the extent to which our model can
predict events in a Scottish population that did not inform the
development of the model. WOSCOPS was a randomised trial
investigating the effectiveness of pravastatin in preventing CHD
in asymptomatic men aged between 45 and 64 years. Further
details of the validation exercise are shown in the online supple-
mentary appendix.
Predicted life expectancies were obtained from a model
where the risk factor values are provided by average values from
the Scottish Health Survey 2009.19 These predicted life expect-
ancies were compared with life expectancies published in GRO
life tables.20 A calibration factor was used to adjust the linear
predictor of the Gompertz regressions for ﬁrst events to minim-
ise the root mean square error between the predicted and
observed life expectancy values for individuals aged 40, 60 and
80 years.
RESULTS
Description of demographics and event outcomes
A total of 16 560 SHHEC participants were free of CVD at
baseline, 8611 (52%) were women. The distribution of risk
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factors is shown in table 1. The median survival time to ﬁrst
event was 20.8 years (IQR 14.5, 23.6 years). A total of 6175
people (37.3%) had a ﬁrst event observed during the follow-up
period.
Illustration of the three modelling stages
We illustrate how the model moves from risk of events to
remaining life expectancy using the following individual proﬁle:
60-year-old man, no family history of CVD, non-diabetic,
SIMD score of 60.8, SBP of 160 mm Hg, TC of 7 mmol/L,
HDL of 1 mmol/L and 20 CPD. The predicted cumulative inci-
dence of the four ﬁrst events and survival probabilities after a
ﬁrst non-fatal event (as well as the survival model estimates that
produce the predictions) are detailed in the online supplemen-
tary appendix.
Table 2 shows how life expectancy is estimated. The top
panel of table 2 shows remaining life expectancy estimated at
the end of every cycle and for each of the four ﬁrst events. For
example, at the end of cycle 24 the estimated life expectancy
for a man experiencing a non-fatal CHD event at that time is
the 24 years alive and event free plus 3.3 years, which is the
estimated life expectancy following the event. The probabilities
of having a ﬁrst event for each cycle are shown in the middle
panel of table 2. These are obtained from the cumulative inci-
dence curves by subtracting the cumulative probability from the
previous year from the current year. The bottom panel of table
2 shows the weighted life expectancies which are obtained by
multiplying together the values in the corresponding cells in the
previous two panels. The sum of all the cells in the bottom
panel of table 2 is the remaining expected life expectancy,
which for this illustration equals 14.07 years (so life expectancy
is 60+14.07=74.07 years).
Discrimination, validation and calibration of model
The discrimination of all statistical models was good with
c-statistics in the range 0.65–0.80 (see online supplementary
appendix). Discrimination was better for the ﬁrst event models
than the models following a ﬁrst non-fatal event, better for the
fatal CVD outcome compared with the other competing ﬁrst
events, and generally better for models for women than for
men.
Figure 2 shows the comparison between observed cumulative
incidence of ﬁrst events from WOSCOPS with predictions made
Figure 1 Structure of the state
transition model. CBVD,
cerebrovascular disease; CHD, coronary
heart disease; CPD, cigarettes per day;
CVD, cardiovascular disease; HDL,
high-density lipoprotein cholesterol
(mmol/L); SIMD, Scottish Index of
Multiple Deprivation; SBP, systolic
blood pressure (mm Hg); TC, total
cholesterol (mmol/L).
Table 1 Demographics of SHHEC participants free of
cardiovascular disease at baseline
Men Women
Cohort size 7949 8611
Age (years) 48.6 (9.3) 48.6 (9.3)
SIMD groups (fifths), n (%):
1 (least deprived) 1390 (17.5) 1467 (17.0)
2 1197 (15.1) 1214 (14.1)
3 1264 (15.9) 1364 (15.8)
4 1479 (18.6) 1675 (19.5)
5 (most deprived) 2619 (32.9) 2891 (33.6)
Diabetes, n (%) 125 (1.6) 117 (1.4)
Family history, n (%) 2061 (25.9) 2788 (32.4)
Cigarette smokers, n (%) 3083 (39.2) 3317 (38.9)
CPD 20.4 (10.2) 16.8 (7.9)
SBP (mm Hg) 133.6 (19.3) 129.7 (21.0)
TC (mmol/L) 6.2 (1.2) 6.4 (1.3)
HDL (mmol/L) 1.3 (0.5) 1.6 (0.4)
Statistics are mean (SD) unless otherwise stated; cigarettes per day (CPD) statistics
are reported for smokers only.
HDL, high-density lipoprotein; SBP, systolic blood pressure; SHHEC, Scottish Heart
Health Extended Cohort; SIMD, Scottish Index of Multiple Deprivation; TC, total
cholesterol.
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with our model. For the placebo arm, the predicted line falls
well within the CI limits for non-fatal CBVD and fatal CVD
events. However, the model underpredicts for non-fatal CHD
and overpredicts for fatal non-CVD. The latter may be
explained by the fact that WOSCOPS is a clinical trial where
stringent exclusion criteria can result in lower mortality than
observed in the general population. For the treatment arm, the
agreement is good for all cardiovascular endpoints (given the
exclusion of cancers from the trial), illustrating that the model
has the potential to predict the impact of CVD interventions.
Without applying a calibration factor, the original model over-
predicted life expectancy. After applying a calibration factor (see
online supplementary appendix for details), all model estimates
were within half a year of life table estimates with the exception
of 80-year-old women.
Illustration of life expectancies
The online supplementary table shows predicted life expectan-
cies for men and women across a wide range of individual
proﬁles. The table shows how age, SBP, cholesterol, smoking
(where ‘smoker’ is deﬁned as somebody smoking 20 CPD) and
SIMD inﬂuence life expectancy while holding diabetes
and family history of heart disease constant at their average
values. It can be seen that even after adjusting for traditional
CVD risk factors, socioeconomic deprivation has a large impact
on life expectancy. To illustrate the socioeconomic deprivation
gradient, ﬁgure 3 shows the predicted life expectancies for
60-year olds across ranked ﬁfths of SIMD scores (within each
ranked group average values risk factor values were obtained
from the Scottish Health Survey 2009). The difference in pre-
dicted life expectancy using the SII to compare the least and
Table 2 Process of estimating life expectancy
Conditional life years remaining (event type and timing)
Cycle (time in years) Non-fatal CHD Non-fatal CBVD Fatal CVD Fatal non-CVD
1 15.6 14.2 1.0 1.0
2 15.8 14.5 2.0 2.0
3 16.1 14.8 3.0 3.0
.
.
22 25.8 25.9 22.0 22.0
23 26.5 26.7 23.0 23.0
24 27.3 27.4 24.0 24.0
.
.
100 100.5 100.5 100.0 100.0
Probability of event occurring (event type and timing)
Cycle (time in years) Non-fatal CHD Non-fatal CBVD Fatal CVD Fatal non-CVD
1 0.023 0.008 0.016 0.013
2 0.023 0.008 0.016 0.013
3 0.023 0.008 0.016 0.013
.
.
22 0.003 0.002 0.004 0.003
23 0.002 0.002 0.003 0.002
24 0.002 0.001 0.002 0.002
.
.
100 0.000 0.000 0.000 0.000
Weighted remaining life years (estimates from top panel multiplied by estimates from middle panel)
Cycle (time in years) Non-fatal CHD Non-fatal CBVD Fatal CVD Fatal non-CVD Sum
1 0.361 0.108 0.016 0.013 0.498
2 0.365 0.113 0.032 0.026 0.537
3 0.368 0.119 0.049 0.040 0.576
.
.
22 0.084 0.057 0.079 0.067 0.286
23 0.066 0.046 0.064 0.054 0.230
24 0.050 0.036 0.050 0.043 0.179
.
.
100 0.000 0.000 0.000 0.000 0.000
Total life years remaining (cumulative sum over each model cycle)= 14.07
Overall life expectancy (age upon entering model plus life years remaining)= 74.07
CBVD, cerebrovascular disease; CHD, coronary heart disease; CVD, Cardiovascular Disease.
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most deprived groups is 6.8 and 5.7 years for men and women,
respectively.
DISCUSSION
Summary
This paper introduces an alternative CVD Policy Model, which
includes a measure of socioeconomic deprivation as an inde-
pendent risk factor. The inputs to the statistical models are the
ASSIGN risk factors and the output is predicted life expectancy.
By including a measure of socioeconomic deprivation as one of
the risk factors, the model can account for disparity in life
expectancy according to the deprivation.
Comparison with other studies
There are many CVD/CHD policy models in the existing litera-
ture and they vary considerably in their methodology. In this
section, we consider models that have used life expectancy as
the outcome for evaluating the effectiveness of interventions.
The CHD policy model21 is a state transition model developed
in the USA. It has been used to evaluate the cost-effectiveness of
both primary and secondary prevention strategies.22 In a later
application,23 the model was used to evaluate the impact of risk
factor modiﬁcation on life expectancy. Like our model, it used a
nationally representative survey to obtain baseline distributions
of risk factors but unlike our model it used relative risks from
Framingham risk equations in conjunction with national mortal-
ity rates to estimate annual incidence rates of CHD and
non-CHD events, rather than following up the survey
participants as a cohort study. Unlike our model, it did not
include a measure of socioeconomic deprivation.
The IMPACT CHD mortality model24 was developed to esti-
mate the fall in CHD mortality in Scotland attributable to treat-
ment and risk factor change in Scotland between 1975 and 1994.
It was later used25 to estimate the attributable gains in terms of life
years by multiplying the number of deaths prevented/postponed
by estimates of median survival taken from Scottish cohort studies
linked to national morbidity and mortality records. In the original
paper, the reduction in CHD deaths caused by changes in socio-
economic deprivation over time was calculated. The components
of this model were obtained from various sources to obtain, for
example, percentage reduction in mortality to be expected from
one percentage change in risk factors.
The heart protection study was originally a randomised con-
trolled study that demonstrated both the effectiveness and the
cost-effectiveness of simvastatin.26 In a later application the cost-
effectiveness of simvastatin was evaluated for remaining life
expectancy of the trial population for a range of different risks
of vascular disease and age groups.27 This evaluation was per-
formed using a Markov state transition model and internally
validated by comparing observed with predicted number of
events. Unlike our cohort, the trial participants had a history of
CVD or were being treated for hypertension. Alongside the
treatment effect, many risk factors, including creatinine which
was not part of our models (but no measure of socioeconomic
deprivation), were used in parametric survival risk equations for
vascular endpoints.
Figure 2 A and B, Validation of model predictions using West of Scotland Coronary Prevention Study trial population. CBVD, cerebrovascular
disease; CHD, coronary heart disease; CVD, cardiovascular disease.
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The Rotterdam Ischaemic heart disease & Stroke Computer
(RISC) model28 is a state transition model which has been exter-
nally validated.29 The states of the model are similar to ours but
also includes a state for CHD and stroke. Although many risk
factors are considered, socioeconomic deprivation was not
included. Like our model, the baseline distribution of risk factors
and the risk equations for predicting model transition probabilities
come from a cohort that has been followed up. The main
difference in modelling strategy is that RISC uses a Monte
Carlo–Markov framework for obtaining transition probabilities,
whereas our approach uses competing risk parametric survival
models.
Strengths
A major strength of this model is the data source. The SHHEC
survey linked to national hospital discharge and death records
allows individuals to be followed up for a long time (median
survival time to ﬁrst event was almost 21 years). The linked data
set allowed us to undertake a competing risk analysis to estimate
the association between risk factors and CVD (and non-CVD)
Figure 2 Continued
Figure 3 Predicted life expectancy
for ranked ﬁfths of socioeconomic
deprivation (SIMD) scores.
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outcomes using a single cohort of individuals. This is a more
sophisticated approach than CVD risk scores based on a single
composite endpoint where the estimate of CVD risk does not
take into account competing causes. Furthermore, the inclusion
of a measure of socioeconomic deprivation as an independent
risk factor is congruent with an inequalities policy agenda,
which is a particular priority in Scotland. In addition, the risk
factors measured in SHHEC were carefully standardised and the
data were very complete. Further strengths are that we have
reported the performance of the model to discriminate over the
observed follow-up period, shown how our model predictions
compare with observed data from an external source, and taken
into account and reported on how well our model is calibrated.
Limitations
Although there was long follow-up, over 60% of individuals
were still to experience a ﬁrst event at the end of the observa-
tion period. Therefore, it was necessary to extrapolate survival
curves and we had to use a calibration factor to ensure that the
average differences between model predictions and life table
estimates of life expectancy were within 1 year. A second limita-
tion is that modiﬁable risk factors were only measured at base-
line with no follow-up measurement occasions. As we intend
this model to be used to assess primary prevention interventions
we do not view this as a major drawback. However, for targeted
interventions any attributed gains in life expectancy could be
exaggerated if beneﬁcial changes to other modiﬁable risk factors
not inﬂuenced by the intervention under study occur. Third, the
ﬁrst events we modelled were hospitalisations and so less serious
CHD and CBVD events that could be treated in a primary care
setting are not explicitly modelled as a health state but any
future hospitalisation(s) for such patients would be captured.
Fourth, as well as capturing the true effect of socioeconomic
deprivation, SIMD will be acting as a proxy for unmeasured
risk factors and complex causal pathways involving SIMD,
unmeasured variables and the interaction between them. As
such, it is likely that any predicted gradient in socioeconomic
deprivation using SIMD will be an overestimation of the true
inequality in life expectancies. Finally, in our validation exercise,
our model predictions were different to WOSCOPS for non-
fatal CHD and fatal non-CVD endpoints. Although this could
be partly due to differences between trial populations and
general populations, we acknowledge that our external valid-
ation results were suboptimal and in future research we would
like to repeat this exercise with another external data source
(which includes women).
The model was developed using Scottish data sources
(SHHEC and the ASSIGN risk variables), including a
Scottish-speciﬁc measure of deprivation. It is intended for use in
Scotland, in the ﬁrst instance. Nonetheless, the model may have
wider generalisability. It is common for models developed in
one setting to be recalibrated for use elsewhere. For instance,
the Framingham risk score has been recalibrated for use outside
of the USA, such as in England.30 A similar exercise could, in
principle, be undertaken for the proposed policy model intro-
duced in this paper.
Public health and clinical implications
Our model can be used to estimate the impact of primary pre-
vention interventions on life expectancy and can assess the
impact of interventions on inequalities. Furthermore, our model
can be used at the local level for predicting future burden of
disease to aid planning and allocation of services. As well as
being able to predict 5-year, 10-year and lifetime risk of CVD
outcomes given risk factor values for an individual, it can also
predict life expectancy. This can help answer patient questions
such as ‘how much longer can I expect to live if I take part in
this intervention?’ and also be used as a tool to prioritise indivi-
duals for intervention.
Key messages
What is already known on this subject?
Cardiovascular disease (CVD; rheumatic heart diseases,
hypertensive diseases, ischaemic heart diseases, pulmonary
heart disease, other forms of heart disease, cerebrovascular
diseases, diseases of arteries and diseases of veins) is a leading
cause of premature mortality, morbidity and health service
costs. The incidence of CVD has also been shown to be socially
patterned. The primary prevention of CVD is a policy priority,
including the objective to reduce health inequalities. A policy
model is a model capable of evaluating the effectiveness and
cost-effectiveness of a wide range of interventions aimed at
modifying known CVD risk factors.
What might this study add?
This policy model joins together risk estimation, individual
patient decision making and societal policy making. By taking a
competing risk approach the model estimates the impact of risk
factor modiﬁcation on CVD events and non-CVD mortality to
predict life expectancy. By including a measure of
socioeconomic deprivation as an independent risk factor the
policy model can be used to assess the impact of interventions
on health inequalities.
How might this impact on clinical practice?
This policy model uses the ASSIGN risk factors to estimate CVD
risk and can project the full impact of risk factor modiﬁcation
on life expectancy. Consequently, the model can be used
consistently as both a clinical and policy tool, to help prioritise
individuals for intervention and to evaluate the effectiveness
and cost-effectiveness of interventions.
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